Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014's crop of startups.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bouchie, A., DeFrancesco, L. Nature Biotechnology's academic spinouts of 2014. Nat Biotechnol 33, 247–255 (2015). https://doi.org/10.1038/nbt.3163
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3163
This article is cited by
-
Evolution of CAR T-cell immunotherapy in terms of patenting activity
Nature Biotechnology (2019)
-
Advances in organ-on-a-chip engineering
Nature Reviews Materials (2018)
-
CRISPR therapeutics push into human testing
Nature Biotechnology (2017)
